Proteome Sciences (LSE:PRM) OCF Margin %: 44.81% (As of Dec. 2025)


What is Proteome Sciences OCF Margin %?

Proteome Sciences LSE:PRM +11.92% OCF Margin % is 44.81% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Proteome Sciences ranks worse than 59.8% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Proteome Sciences's Cash Flow from Operations for the six months ended in Dec. 2025 was £0.85 Mil. Proteome Sciences's Revenue for the six months ended in Dec. 2025 was £1.90 Mil. Therefore, Proteome Sciences's OCF Margin % for the quarter that ended in Dec. 2025 was 44.81%.

As of today, Proteome Sciences's current OCF Yield % is -0.87%.

The historical rank and industry rank for Proteome Sciences's OCF Margin % or its related term are showing as below:

LSE:PRM' s OCF Margin % Range Over the Past 10 Years
Min: -72.67   Med: -5.4   Max: 33.31
Current: -1.22

During the past 13 years, the highest OCF Margin % of Proteome Sciences was 33.31%. The lowest was -72.67%. And the median was -5.40%.

LSE:PRM's OCF Margin % is ranked worse than
59.8% of 204 companies
in the Medical Diagnostics & Research industry
Industry Median: 4.755 vs LSE:PRM: -1.22

Proteome Sciences OCF Margin % Related Terms

Proteome Sciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for Proteome Sciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proteome Sciences OCF Margin % Chart

Proteome Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.46 27.51 -9.57 -16.90 -1.22

Proteome Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.06 -23.18 -11.69 -48.30 44.81

LSE:PRM vs TMO, DHR, IDXX: OCF Margin % Comparison

For the Diagnostics & Research subindustry, Proteome Sciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proteome Sciences OCF Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Proteome Sciences's OCF Margin % falls into.


Proteome Sciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Proteome Sciences's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-0.046/3.756
=-1.22 %

Proteome Sciences's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0.851/1.899
=44.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 44.81% mean?
Proteome Sciences (LSE:PRM) has a OCF Margin % of 44.81% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Proteome Sciences and its competitors. According to the industry distribution chart, Proteome Sciences ranks #122 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 59.8%.
Is Proteome Sciences' OCF Margin % too high?
Proteome Sciences' current OCF Margin % is 44.81%. The Medical Diagnostics & Research industry median OCF Margin % is 4.76. Proteome Sciences' value of 44.81% is 842.4% above this industry median. Based on the distribution chart, Proteome Sciences ranks #122 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Proteome Sciences' OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #122 out of 204 companies for OCF Margin %. This places Proteome Sciences in the lower half of its industry. The industry median OCF Margin % is 4.76. Proteome Sciences' value of 44.81% is 842.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.76, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteome Sciences's current OCF Margin % of 44.81% is 842.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Proteome Sciences and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteome Sciences's current OCF Margin % is 44.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (LSE:PRM) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.02, compared to a current price of £0.02 — trading 15.5% below its estimated fair value. The current OCF Margin % is 44.81% and 842.4% above the Medical Diagnostics & Research industry median of 4.76. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Proteome Sciences (LSE:PRM), the current OCF Margin % is 44.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Proteome Sciences Business Description

Other Exchanges PRMl:UKPI2:Germany
Address Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.